Drug Ther Bull. 1998 Nov;36(11):81-4.
At any one time, around 10% of men are unable to achieve and/or maintain an erection sufficient for satisfactory sexual activity, a condition known as erectile dysfunction. Several mechanical, surgical and medical approaches have been developed for the treatment of this problem but none are ideal. Sildenafil (Viagra-Pfizer), a selective phosphodiesterase inhibitor, is the first licensed oral drug treatment for erectile dysfunction. It was marketed in the UK in October 1998, at which time the Department of Health was advising doctors that they "should not prescribe sildenafil" and that health authorities should not "support the provision of sildenafil at NHS expense to patients requiring treatment for erectile dysfunction, other than in exceptional circumstances". Here we review sildenafil for the management of erectile dysfunction and discuss whether it should be available on the NHS.
在任何时候,约10%的男性无法勃起和/或维持足以进行满意性活动的勃起状态,这种情况被称为勃起功能障碍。已经开发出多种机械、手术和药物治疗方法来解决这一问题,但均不尽人意。西地那非(辉瑞公司的万艾可)是一种选择性磷酸二酯酶抑制剂,是首个获得许可用于治疗勃起功能障碍的口服药物。它于1998年10月在英国上市,当时卫生部建议医生“不应开具西地那非处方”,且卫生当局不应“支持国民保健制度(NHS)为需要治疗勃起功能障碍的患者支付西地那非费用,特殊情况除外”。在此,我们对西地那非治疗勃起功能障碍进行综述,并讨论它是否应由国民保健制度提供。